TECH - Bio-Techne Corp Stock Price, Fair Value and News

63.12USD+0.46 (+0.73%)Market Closed as of 26 Apr 2024, 09:45 am ET

Market Summary

USD63.12+0.46

Market Closedas of 26 Apr 2024, 09:45 am

0.73%

TECH Stock Price

View Fullscreen

TECH RSI Chart

TECH Valuation

Market Cap

9.9B

Price/Earnings (Trailing)

43.96

Price/Sales (Trailing)

8.6

EV/EBITDA

27.05

Price/Free Cashflow

43.71

TECH Price/Sales (Trailing)

TECH Profitability

EBT Margin

21.96%

Return on Equity

11.41%

Return on Assets

8.21%

Free Cashflow Yield

2.29%

TECH Fundamentals

TECH Revenue

Revenue (TTM)

1.1B

Rev. Growth (Yr)

0.37%

Rev. Growth (Qtr)

-1.57%

TECH Earnings

Earnings (TTM)

224.1M

Earnings Growth (Yr)

-45.08%

Earnings Growth (Qtr)

-46.14%

Breaking Down TECH Revenue

52 Week Range

62.6589.91

(Low)(High)

Last 7 days

0.7%

Last 30 days

-8.4%

Last 90 days

-13.7%

Trailing 12 Months

-20.1%

How does TECH drawdown profile look like?

TECH Financial Health

Current Ratio

4.37

Debt/Equity

0.23

Debt/Cashflow

0.62

TECH Investor Care

Dividend Yield

0.45%

Dividend/Share (TTM)

0.32

Buy Backs (1Y)

0.05%

Diluted EPS (TTM)

1.38

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	1.1B	1.1B	1.1B	1.1B
2022	1.1B	1.1B	1.1B	1.1B
2021	847.8M	931.0M	984.6M	1.0B
2020	754.5M	738.7M	759.6M	799.0M
2019	702.6M	714.0M	734.3M	744.7M
2018	619.3M	643.0M	661.4M	681.7M
2017	541.2M	563.0M	577.0M	599.4M
2016	481.9M	499.0M	517.2M	528.1M
2015	434.3M	452.2M	456.1M	465.1M
2014	344.7M	357.8M	380.6M	398.5M
2013	309.8M	310.6M	321.2M	330.2M
2012	313.9M	314.6M	312.0M	312.4M
2011	278.6M	290.0M	299.6M	306.6M
2010	267.8M	269.0M	270.5M	272.6M
2009	0	264.0M	265.2M	266.5M

Get all data in R, Python etc through our Historical Stock Data APIs

GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed S&P 500 Index

Grufity's Fair Value model takes all the S&P 500 stocks and divides them into separate buckets based on their attractiveness. The 'Very Cheap' bucket of S&P 500 has greatly outperformed S&P 500 Index. Conversely, S&P500 stocks considered 'Very Expensive' by the model underperformed the S&P500 index in the past three years. Grufity Fair Value is available for 2300+ stocks, including 90% of S&P 500 stocks. Grufity's Fair Value Model separates high-return stocks from low-return stocks.

Returns of $10,000 invested in:

Very Cheap Stocks: $17,289
S&P 500 Index: $12,922
Very Expensive Stocks: $11,022

Grufity's Fair Value model does a great job in separating High Performing Stocks from Low Performing ones in the S&P 500 list.

S&P 500 Index

Very Expensive Stocks

Very Cheap Stocks

Try For Just $1.99

Tracking the Latest Insider Buys and Sells of Bio-Techne Corp

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 03, 2024	bohnen shane	acquired	-	-	2,259	svp - general counsel
Apr 03, 2024	bohnen shane	sold (taxes)	-50,698	67.87	-747	svp - general counsel
Mar 07, 2024	nusse roeland	sold	-800,627	76.9834	-10,400	-
Feb 01, 2024	geist william	sold (taxes)	-76,147	68.54	-1,111	president, protein sciences
Dec 19, 2023	hippel james	acquired	1,478,250	31.26	47,289	cfo
Dec 19, 2023	hippel james	sold (taxes)	-2,552,230	77.42	-32,966	cfo
Nov 01, 2023	kelderman kim	acquired	-	-	14,196	chief operating officer
Oct 26, 2023	steer randolph c	acquired	-	-	1,625	-
Oct 26, 2023	vessey rupert	acquired	-	-	1,625	-
Oct 26, 2023	keegan joseph d	acquired	-	-	1,625	-

Which funds bought or sold TECH recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 24, 2024	DekaBank Deutsche Girozentrale	added	3.46	-110,000	1,239,000	-%
Apr 24, 2024	RAYMOND JAMES TRUST N.A.	added	9.49	-674	592,685	0.01%
Apr 24, 2024	Robeco Institutional Asset Management B.V.	sold off	-100	-252,777	-	-%
Apr 24, 2024	CENTRAL TRUST Co	unchanged	-	-6,689	69,546	-%
Apr 24, 2024	FORT WASHINGTON INVESTMENT ADVISORS INC /OH/	unchanged	-	-	18,387,800	0.13%
Apr 24, 2024	Financial Freedom, LLC	unchanged	-	-2,688	28,309	0.02%
Apr 24, 2024	Cambridge Investment Research Advisors, Inc.	reduced	-2.08	-94,000	786,000	-%
Apr 24, 2024	Spire Wealth Management	reduced	-99.7	-4,148,540	12,434	-%
Apr 24, 2024	Simplicity Wealth,LLC	new	-	218,491	218,491	-%
Apr 24, 2024	LEAVELL INVESTMENT MANAGEMENT, INC.	reduced	-18.97	-1,293,000	3,664,000	0.21%

Are Funds Buying or Selling TECH?

Are funds buying TECH calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own TECH

No. of Funds

Unveiling Bio-Techne Corp's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 13, 2024	vanguard group inc	11.53%	18,228,210	SC 13G/A
Jan 24, 2024	blackrock inc.	11.5%	18,133,912	SC 13G/A
Feb 09, 2023	vanguard group inc	11.59%	18,199,432	SC 13G/A
Jan 26, 2023	blackrock inc.	10.1%	15,888,640	SC 13G/A
Jan 20, 2023	blackrock inc.	10.1%	15,888,640	SC 13G
Feb 09, 2022	vanguard group inc	11.27%	4,426,638	SC 13G/A
Jan 27, 2022	blackrock inc.	11.0%	4,328,299	SC 13G/A
Jan 25, 2022	blackrock inc.	11.0%	4,328,299	SC 13G/A
Sep 10, 2021	vanguard group inc	11.04%	4,315,543	SC 13G/A
Feb 10, 2021	vanguard group inc	9.30%	3,591,352	SC 13G/A

Recent SEC filings of Bio-Techne Corp

View All Filings

Date Filed	Form Type	Document
Apr 05, 2024	4	Insider Trading
Mar 11, 2024	4	Insider Trading
Mar 07, 2024	144	Notice of Insider Sale Intent
Feb 13, 2024	SC 13G/A	Major Ownership Report
Feb 07, 2024	10-Q	Quarterly Report
Feb 05, 2024	4	Insider Trading
Feb 05, 2024	4	Insider Trading
Feb 05, 2024	4	Insider Trading
Feb 05, 2024	3	Insider Trading
Feb 01, 2024	8-K	Current Report

Peers (Alternatives to Bio-Techne Corp)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	40.6B	6.8B	-1.15%	-18.78%	-8.61	5.92	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.1B	1.8B	-5.46%	-27.26%	-41.1	9.9	76.23%	61.08%
BMRN	15.5B	2.4B	-6.36%	-11.66%	92.47	6.41	15.42%	18.43%
INCY	11.5B	3.7B	-9.50%	-30.40%	19.23	3.11	8.87%	75.42%
MID-CAP
APLS	5.8B	396.6M	-18.85%	-43.46%	-10.93	14.57	425.83%	18.94%
BBIO	4.3B	-	-18.25%	70.26%	-6.55	60.35	54.84%	-34.79%
AXSM	3.4B	270.6M	-6.76%	2.03%	-14.16	12.52	440.80%	-27.84%
ARWR	2.7B	240.7M	-21.52%	-38.49%	-9.13	12.18	-1.03%	-92.09%
ACAD	2.7B	726.4M	-8.32%	-19.69%	-43.85	3.7	40.45%	71.62%
SMALL-CAP
CPRX	1.7B	398.2M	-6.79%	-8.36%	24.23	4.35	85.90%	-14.05%
NVAX	552.8M	983.7M	-16.14%	-47.54%	-1.01	0.56	-50.36%	17.16%
CRBP	351.2M	881.7K	-7.41%	335.24%	-7.87	466.16	-77.61%	-5.33%
INO	236.5M	4.9M	-18.26%	4.12%	-1.75	48.6	-54.97%	51.71%
IBIO	5.9M	2.1M	47.83%	55.96%	-0.22	2.14	-13.45%	66.37%

Bio-Techne Corp News

Latest updates

Bio-Techne Corp Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Income Statement (Quarterly)																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Revenue	-1.6%	273	277	301	294	272	270	288	290	269	258	259	244	224	204	176	195	185	183	192	185	175
Gross Profit	-4.6%	177	185	205	202	183	180	200	201	184	171	176	168	151	138	113	130	121	118	128	125	113
Operating Expenses	7.2%	139	129	110	122	115	123	120	111	121	108	107	100	100	89.00	74.00	82.00	84.00	85.00	85.00	81.00	79.00
S&GA Expenses	9.8%	116	105	87.00	99.00	93.00	99.00	97.00	89.00	101	86.00	87.00	83.00	83.00	73.00	57.00	66.00	68.00	69.00	69.00	65.00	64.00
EBITDA Margin	-7.5%	0.33*	0.35*	0.40*	0.40*	0.39*	0.40*	0.37*	0.32*	0.30*	0.28*	0.27*	0.36*	-	-	-	-	-	-	-	-	-
Interest Expenses	-9.5%	4.00	5.00	5.00	0.00	2.00	3.00	3.00	2.00	3.00	3.00	3.00	3.00	4.00	4.00	5.00	4.00	5.00	5.00	5.00	-2.52	16.00
Income Taxes	512.7%	6.00	-1.43	13.00	10.00	16.00	14.00	17.00	9.00	14.00	-1.60	-7.53	-0.05	10.00	6.00	3.00	10.00	31.00	3.00	6.00	5.00	4.00
Earnings Before Taxes	-32.6%	33.00	50.00	88.00	80.00	66.00	104	79.00	69.00	86.00	67.00	7.00	45.00	56.00	39.00	62.00	47.00	150	18.00	23.00	50.00	22.00
EBT Margin	-11.7%	0.22*	0.25*	0.30*	0.29*	0.28*	0.30*	0.27*	0.21*	0.20*	0.18*	0.16*	0.24*	-	-	-	-	-	-	-	-	-
Net Income	-46.1%	27.00	51.00	75.00	70.00	50.00	90.00	66.00	61.00	72.00	69.00	15.00	46.00	46.00	33.00	59.00	36.00	120	14.00	16.00	45.00	18.00
Net Income Margin	-9.2%	0.20*	0.22*	0.25*	0.25*	0.24*	0.26*	0.24*	0.20*	0.20*	0.18*	0.15*	0.22*	-	-	-	-	-	-	-	-	-
Free Cashflow	49.1%	68.00	46.00	73.00	39.00	58.00	47.00	89.00	58.00	91.00	42.00	111	64.00	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	-0.9%	2,731	2,755	2,639	2,600	2,363	2,351	2,295	2,300	2,305	2,270	2,263	2,085	2,068	2,053	2,028	1,999	1,998	1,925	1,884	1,873	1,845
Current Assets	-0.1%	591	591	621	571	565	552	606	593	590	544	511	567	542	542	521	492	465	392	413	423	380
Cash Equivalents	-12.5%	130	149	181	127	165	165	173	161	212	196	199	186	166	169	147	156	110	100	101	96.00	86.00
Inventory	-2.8%	181	186	172	169	160	150	141	128	122	117	117	110	107	106	103	100	95.00	91.00	91.00	94.00	91.00
Net PPE	1.1%	234	232	226	224	224	224	223	218	212	207	208	199	196	192	177	165	164	157	154	145	145
Goodwill	1.1%	980	969	873	871	870	865	822	828	832	843	843	95.00	728	732	728	726	734	730	733	720	706
Current Liabilities	5.9%	135	128	129	141	128	138	176	167	155	134	152	138	118	105	107	105	105	88.00	102	98.00	87.00
Long Term Debt	1.6%	447	440	350	370	200	265	243	247	270	288	329	203	219	311	344	407	370	474	493	510	533
LT Debt, Current	-	-	-	-	-	-	-	13.00	13.00	13.00	13.00	13.00	13.00	13.00	13.00	13.00	13.00	13.00	13.00	13.00	13.00	-
Shareholder's Equity	-1.7%	1,964	1,998	1,967	1,890	12.00	13.00	1,701	1,713	1,703	1,647	1,571	1,548	1,531	1,439	1,381	1,291	1,323	1,174	1,166	1,146	1,096
Retained Earnings	-5.0%	1,261	1,328	1,309	1,247	1,200	1,163	1,123	1,133	1,146	1,119	1,085	1,089	1,105	1,073	1,057	1,013	1,039	931	932	928	895
Additional Paid-In Capital	2.4%	764	747	722	715	701	680	652	636	616	584	534	514	481	449	421	382	363	334	317	298	284
Shares Outstanding	-0.8%	157	158	158	157	157	157	157	157	157	156	155	155	-	-	-	-	-	-	-	-	-
Minority Interest	-	-	-	-	-	-	-	-0.76	-1.05	-0.46	8.00	8.00	8.00	9.00	-	-	-	-	-	-	-	-
Float	-	-	-	-	-	13,000	-	-	-	20,300	-	-	-	12,400	-	-	-	8,400	-	-	-	5,500

Cashflow (Last 12 Months)

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Cashflow (Quarterly)																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	40.0%	83.00	59.00	83.00	51.00	64.00	56.00	103	73.00	101	48.00	122	75.00	89.00	66.00	45.00	49.00	70.00	41.00	56.00	40.00	47.00
Share Based Compensation	26.4%	13.00	10.00	-2.08	10.00	17.00	14.00	8.00	8.00	14.00	12.00	10.00	11.00	16.00	13.00	6.00	8.00	10.00	8.00	8.00	6.00	7.00
Cashflow From Investing	84.6%	-23.67	-154	-4.76	-241	-0.11	-19.69	-18.57	-35.99	-35.17	-7.12	-226	0.00	-8.60	-8.14	-10.47	19.00	33.00	-15.08	-30.32	-4.74	-13.63
Cashflow From Financing	-213.8%	-81.40	72.00	-24.22	151	-72.19	-31.81	-65.73	-84.06	-53.38	-39.68	118	-55.23	-90.08	-34.93	-44.72	-17.79	-97.03	-24.27	-19.90	-27.04	-41.21
Dividend Payments	-0.8%	13.00	13.00	13.00	13.00	13.00	13.00	13.00	13.00	13.00	12.00	12.00	12.00	12.00	12.00	12.00	12.00	12.00	12.00	12.00	12.00	12.00
Buy Backs	-	-	-	-	-	-	20.00	59.00	61.00	-	-	-	43.00	-	-	-	50.00	-	-	-	0.00	-

TECH Income Statement

2023-12-31

CONDENSED CONSOLIDATED STATEMENTS OF EARNINGS AND COMPREHENSIVE INCOME - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2023	Dec. 31, 2022
CONDENSED CONSOLIDATED STATEMENTS OF EARNINGS AND COMPREHENSIVE INCOME
Net sales	$ 272,598	$ 271,581	$ 549,533	$ 541,236
Cost of sales	96,011	88,221	187,755	178,280
Gross margin	176,587	183,360	361,778	362,956
Operating expenses:
Selling, general and administrative	115,667	93,010	220,998	192,386
Research and development	22,916	22,459	46,914	46,362
Total operating expenses	138,583	115,469	267,912	238,748
Operating income	38,004	67,891	93,866	124,208
Other income (expense)	(4,617)	(1,462)	(10,921)	45,938
Earnings before income taxes	33,387	66,429	82,945	170,146
Income taxes (benefit)	5,922	16,424	4,486	30,407
Net earnings, including noncontrolling interest	27,465	50,005	78,459	139,739
Net earnings attributable to noncontrolling interest				179
Net earnings attributable to Bio-Techne	27,465	50,005	78,459	139,560
Other comprehensive income (loss):
Foreign currency translation income (loss)	18,025	17,370	6,423	(4,087)
Foreign currency translation reclassified to earnings with Eminence deconsolidation				119
Unrealized gains (losses) on derivative instruments - cash flow hedges, net of tax amounts disclosed in Note 8	(3,670)	(685)	(4,020)	4,010
Other comprehensive income (loss)	14,355	16,685	2,403	42
Other comprehensive income (loss) attributable to noncontrolling interest				(33)
Other comprehensive income (loss) attributable to Bio-Techne	14,355	16,685	2,403	75
Comprehensive income attributable to Bio-Techne	$ 41,820	$ 66,690	$ 80,862	$ 139,635
Earnings per share attributable to Bio-Techne:
Basic (in dollars per share)	$ 0.17	$ 0.32	$ 0.50	$ 0.89
Diluted (in dollars per share)	$ 0.17	$ 0.31	$ 0.49	$ 0.86
Weighted average common shares outstanding:
Basic (in shares)	157,533	157,011	157,826	156,887
Diluted (in shares)	160,060	161,750	161,001	161,766

TECH Balance Sheet

2023-12-31

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Dec. 31, 2023	Jun. 30, 2023
Current assets:
Cash and cash equivalents	$ 130,132	$ 180,571
Short-term available-for-sale investments	5,520	23,739
Accounts receivable, less allowance for doubtful accounts of $3,502 and $4,738, respectively	207,451	218,468
Inventories	180,839	171,638
Current assets held-for-sale	26,647
Other current assets	40,051	27,066
Total current assets	590,640	621,482
Property and equipment, net	234,204	226,200
Right of use assets	100,863	98,326
Goodwill	980,082	872,737
Intangible assets, net	550,605	534,645
Other assets	274,359	285,302
Total assets	2,730,753	2,638,692
Current liabilities:
Trade accounts payable	31,514	25,679
Salaries, wages and related accruals	32,995	36,747
Accrued expenses	17,159	14,880
Contract liabilities	28,427	23,069
Income taxes payable	6,646	12,022
Operating lease liabilities - current	12,672	11,199
Contingent consideration payable		3,500
Current liabilities held-for-sale	1,593
Other current liabilities	4,225	1,413
Total current liabilities	135,231	128,509
Deferred income taxes	71,575	88,982
Long-term debt obligations	447,000	350,000
Operating lease liabilities	96,027	93,766
Other long-term liabilities	17,361	10,919
Bio-Techne's Shareholders' equity:
Undesignated capital stock, no par; authorized 5,000,000 shares; none issued or outstanding	0	0
Common stock, par value $.01 per share; authorized 400,000,000; issued and outstanding 157,142,004 and 157,641,914 respectively	1,571	1,576
Additional paid-in capital	764,273	721,543
Retained earnings	1,261,376	1,309,461
Accumulated other comprehensive loss	(63,661)	(66,064)
Total Bio-Techne's shareholders' equity	1,963,559	1,966,516
Total liabilities and shareholders' equity	$ 2,730,753	$ 2,638,692

About Bio-Techne Corp

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets in the United States, the United Kingdom, rest of Europe, Middle East, and Africa, Greater China, rest of Asia-Pacific, and internationally. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.

CEO	Mr. Charles R. Kummeth
WEBSITE	bio-techne.com
INDUSTRY	Biotechnology
EMPLOYEES	3050

Bio-Techne Corp Frequently Asked Questions

What is the ticker symbol for Bio-Techne Corp? What does TECH stand for in stocks?

TECH is the stock ticker symbol of Bio-Techne Corp. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Bio-Techne Corp (TECH)?

As of Thu Apr 25 2024, market cap of Bio-Techne Corp is 9.85 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of TECH stock?

You can check TECH's fair value in chart for subscribers.

What is the fair value of TECH stock?

You can check TECH's fair value in chart for subscribers. The fair value of Bio-Techne Corp is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Bio-Techne Corp is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for TECH so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Bio-Techne Corp a good stock to buy?

The fair value guage provides a quick view whether TECH is over valued or under valued. Whether Bio-Techne Corp is cheap or expensive depends on the assumptions which impact Bio-Techne Corp's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for TECH.

What is Bio-Techne Corp's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu Apr 25 2024, TECH's PE ratio (Price to Earnings) is 43.96 and Price to Sales (PS) ratio is 8.6. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. TECH PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Bio-Techne Corp's stock?

In the past 10 years, Bio-Techne Corp has provided 0.115 (multiply by 100 for percentage) rate of return.